ASOPRS Fall Symposium Will Feature Innovations, Diversity, and Diet Presentations

The American Society of Ophthalmic Plastic & Reconstructive Surgery 2021 Fall Scientific Symposium will feature presentations on oculofacial surgery innovations, social justice and diversity, and more.

Both in-person in New Orleans, Louisiana, and online virtually, the American Society of Ophthalmic Plastic & Reconstructive Surgery (ASOPRS) will meet for the Fall Scientific Symposium, November 11-12, ahead of AAO 2021, the annual meeting of the American Academy of Ophthalmology.

The meeting kicks off both days with presentations from the young members of ASOPRS (YASPORS). These members have 8 years or less of experience after graduation from an ASOPRS-approved fellowship. Some of the topics that these members are presenting are “Orbital Inflammation Following COVID-19 Vaccination,” “Psychogenic Ptosis,” “Patient-Reported Tearing-Related Quality of Life,” and “Epidemiology of Ophthalmic Trauma at a Major Level 1 Trauma Center in the United States: The Denver Health Ophthalmic Trauma Registry (DHOTR).”

Neal Barnard, MD, FACC, adjunct professor of medicine, George Washington University School of Medicine, and president, Physicians Committee for Responsible Medicine, will participate in 2 presentations: the ASOPRS Foundation Michael J. Hawes Lecture on “Power Foods for the Brain,” and “Your Body in Balance: The New Science of Food, Hormones and Health.”

The symposium will also feature Kris Moe, MD, FACS, professor, chair, facial plastic surgery, University of Washington in Seattle. On the first day, he will present the ASOPRS Foundation Ralph E. Wesley Lecture, “Transorbital Neuroendoscopic Surgery: The Orbit as a Gateway to the Skull and Brain,” and on day 2, he will present “Technical Aids in Orbital Reconstruction.”

Throughout the rest of the symposium, the presentations will be split into the pediatric and lacrimal session; 2 eyelid sessions; 2 aesthetics sessions; 2 orbit sessions; an oncology session; a social justice, diversity, and distribution of oculofacial plastic surgeons session; a practice management session; and a thyroid eye disease session. Last year, the FDA approved the first therapy to treat thyroid eye disease, teprotumumab (Tepezza), which has changed the treatment landscape.

The program chairs highlighted the social justice and diversity session, which includes timely presentations on representation in oculoplastics, transgender care, assault-related trauma and social determinants, and social and medical factors associated with loss of eye.

Finally, the symposium will include 2 panels. On day 1, a panel will discuss “Industry and Innovation in Oculofacial Plastic Surgery,” and on day 2, a second panel will tackle “Administrative Leadership.”